Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-002: HS-20093 in Advanced Sarcoma
NCT05830123Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in osteosarcoma (OS), sarcoma, sponsored by Hansoh Pharmaceutical Group. Started Jun 2023; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
osteosarcoma (OS)sarcoma
Beyond the preview
Go deeper on NCT05830123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830123.